Stock listing

NASDAQ:TNYA Tenaya Therapeutics, Inc. Stock

Home listing (NASDAQ) of Tenaya Therapeutics, Inc.

Follow Tenaya Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:TNYA

$0.287 USD -0.020 (-6.6%)

Close on Nov 20, 2026

Past year -75.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.283 – $0.321 USDNov 20, 2026
Volume
4.34M sharesNov 20, 2026
Market cap
$65.32M USDAt the close on Nov 20, 2026 · price × 227.9M shares outstanding
52-week range
$0.283 – $1.460 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.44M USDMedian day 2.28M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Tenaya Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:TNYA · Home$0.287 USD-0.020 (-6.6%)4,341,674$0.290$0.321$0.283$0.307Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TNYA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.287-0.020-6.6%$0.290$0.321$0.2834,341,674
$0.307-0.016-4.9%$0.320$0.339$0.3012,768,797
$0.323-0.011-3.2%$0.330$0.340$0.3115,467,712
$0.334-0.016-4.5%$0.354$0.360$0.3301,686,975
$0.349+0.002+0.5%$0.350$0.358$0.3341,304,557
$0.348-0.024-6.4%$0.372$0.378$0.3402,232,726
$0.371+0.001+0.2%$0.380$0.398$0.3701,039,054
$0.371-0.023-5.9%$0.400$0.408$0.3712,235,445
$0.394+0.034+9.4%$0.374$0.410$0.3672,946,477
$0.360+0.044+14.0%$0.334$0.364$0.3312,907,629
$0.316-0.054-14.6%$0.385$0.386$0.3007,583,380
$0.370+0.010+2.7%$0.375$0.383$0.3661,619,246
$0.360-0.001-0.2%$0.358$0.378$0.3511,661,173
$0.361-0.006-1.7%$0.372$0.381$0.3612,288,058
$0.367-0.031-7.8%$0.394$0.400$0.3662,657,548
$0.398-0.005-1.3%$0.400$0.418$0.3971,778,146
$0.404+0.002+0.6%$0.410$0.415$0.4001,207,851
$0.401-0.007-1.8%$0.420$0.429$0.3932,140,495
$0.409+0.020+5.0%$0.392$0.419$0.3853,439,964
$0.389+0.001+0.3%$0.395$0.397$0.3811,698,850
$0.388-0.002-0.6%$0.395$0.408$0.3861,721,179
$0.390-0.020-4.8%$0.410$0.418$0.3902,185,738
$0.410+0.032+8.6%$0.381$0.419$0.3803,263,258
$0.378-0.003-0.8%$0.380$0.389$0.3623,005,168
$0.381-0.028-6.8%$0.410$0.417$0.3706,836,062
$0.408+0.018+4.6%$0.390$0.430$0.3905,008,043
$0.391-0.131-25.0%$0.500$0.510$0.36018,145,480
$0.521-0.044-7.9%$0.569$0.570$0.5172,562,543
$0.566-0.015-2.6%$0.562$0.577$0.5452,514,683
$0.580+0.036+6.6%$0.539$0.590$0.5384,304,193
$0.544+0.011+2.0%$0.530$0.547$0.5213,637,379
$0.533-0.013-2.4%$0.530$0.555$0.5303,728,075
$0.547-0.018-3.1%$0.570$0.577$0.5422,703,448
$0.5640.0000.0%$0.565$0.577$0.5502,869,375
$0.564-0.002-0.3%$0.570$0.580$0.5613,725,994
$0.566-0.038-6.3%$0.596$0.603$0.5614,755,436
$0.604+0.011+1.8%$0.612$0.625$0.6001,814,762
$0.593+0.003+0.6%$0.590$0.615$0.5901,735,816
$0.590-0.020-3.2%$0.600$0.608$0.5706,083,975
$0.610-0.010-1.7%$0.627$0.640$0.6003,726,260
$0.620-0.041-6.2%$0.660$0.670$0.6203,594,213
$0.661-0.021-3.1%$0.685$0.688$0.6602,920,377
$0.682+0.008+1.2%$0.674$0.700$0.6741,226,633
$0.674-0.006-0.8%$0.680$0.710$0.6723,944,904
$0.679+0.007+1.1%$0.680$0.710$0.6694,873,201
$0.672+0.015+2.2%$0.670$0.688$0.6601,933,232
$0.658-0.013-1.9%$0.662$0.674$0.6501,942,552
$0.671-0.022-3.2%$0.698$0.708$0.6601,841,324
$0.693+0.053+8.3%$0.656$0.709$0.6503,081,623
$0.640-0.009-1.4%$0.665$0.674$0.6401,375,182
$0.649-0.012-1.8%$0.662$0.670$0.6402,283,533
$0.661-0.002-0.4%$0.670$0.690$0.6601,181,604
$0.663-0.020-2.9%$0.685$0.710$0.6612,365,328
$0.683-0.012-1.7%$0.690$0.710$0.6811,206,134
$0.695-0.004-0.6%$0.699$0.710$0.6911,555,103
$0.699+0.014+2.0%$0.698$0.710$0.6901,213,508
$0.685-0.002-0.3%$0.693$0.700$0.6821,080,718
$0.688-0.002-0.3%$0.690$0.697$0.6721,506,951
$0.690-0.005-0.7%$0.701$0.704$0.6871,112,529
$0.695-0.001-0.1%$0.700$0.714$0.6901,244,726
$0.696-0.005-0.7%$0.694$0.715$0.690935,931
$0.701+0.027+4.0%$0.671$0.710$0.6711,743,756
$0.675-0.023-3.2%$0.697$0.700$0.6574,029,676
$0.697+0.007+1.0%$0.693$0.720$0.6931,154,427
$0.691-0.022-3.1%$0.713$0.727$0.6911,528,737
Ticker
NASDAQ:TNYA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Tenaya Therapeutics, Inc. news

Tenaya Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 103 in all · newest Nov 4, 2026 · oldest 2021
Decks
10 decks · latest September 2026

Where Tenaya Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TNYA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:TNYABOATSUnited StatesUSD

Valuation

EV/sales 0.5× against a median of 28.6×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.38M USD
P/E
Loss
EV/sales
0.5×
EV/EBITDA
Negative EBITDA
Price/book
1.2×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.1×
Beta vs S&P 500
2.42

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Tenaya Therapeutics, Inc. · NASDAQ:TNYAUS$65.32MUS$1.38Mn/a0.5×n/a1.2×n/a0.1×2.42
Cingulate Inc. · NASDAQ:CINGUS$67.48MUS$1.21Bn/an/an/a3.3×n/a56.0×1.41
Energenesis Biomedical Co., Ltd. · TWSE:6657US$67.22MUS$47.02Mn/a203×n/a3.1×n/a0.0×n/a
MediciNova, Inc. · NASDAQ:MNOVUS$67.11MUS$38.45Mn/a41.1×n/a1.6×n/a0.0×0.56
Dicot Pharma AB · OMXSTO:DICOTUS$66.61MUS$44.54Mn/an/an/a3.0×n/a0.0×n/a
Cardiff Oncology, Inc. · NASDAQ:CRDFUS$66.34MUS$32.82Mn/a58.7×n/a2.4×n/a0.0×1.32
Polaryx Therapeutics, Inc. · NASDAQ:PLYXUS$66.30MUS$57.86Mn/an/an/a8.7×n/a0.0×1.66
PMV Pharmaceuticals, Inc. · NASDAQ:PMVPUS$66.17M−US$36.25Mn/an/an/a1.2×n/a0.0×1.43
Gossamer Bio, Inc. · NASDAQ:GOSSUS$65.57MUS$55.23Mn/a0.7×n/an/a−159.5%n/a1.56
Atara Biotherapeutics, Inc. · NASDAQ:ATRAUS$64.49MUS$64.14Mn/a16.2×n/an/a−368.6%n/a1.43
AlzeCure Pharma AB · OMXSTO:ALZCURUS$63.88MUS$62.76M21.3×6.6×25.6×7.1×31.6%0.0×n/a
Median of the othersUS$66.32MUS$51.13M21.3×28.6×25.6×3.0×−159.5%0.0×1.43

Forecasts

4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
3.67 USD · Analysts' mean
EPS, year to Dec 2026
-0.44 · 3 analysts
Revenue, year to Dec 2026
3.84M · 4 analysts

Team and board

Officers

OfficerRole
Faraz AliChief Executive Officer
Eric HyllengrenChief Financial Officer
Jennifer DrimmerGeneral Counsel
Jay VoraSenior Vice President, Portfolio and Program Management
Joanna AuchSenior Vice President, People and Culture
Kathy IveySenior Vice President, Research
Kee-Hong KimChief Technology Officer
Whit TingleyChief Medical Officer

Board

DirectorRole
R. Sanders WilliamsChair of the Board
Amy BurroughsBoard Member
Catherine Stehman-BreenBoard Member
Deepak SrivastavaBoard Member
Faraz AliChief Executive Officer
Jeffrey T. WalshBoard Member
June LeeBoard Member
Karah ParschauerBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−14.6%
Q2 2026Aug 5, 2026 · After close−7.5%
Q1 2026May 6, 2026 · After close+7.3%
Q4 2025Mar 24, 2026−3.9%
Q3 2025Nov 10, 2025 · Before open+11.7%
Q2 2025Aug 6, 2025 · After close−1.7%
Q1 2025May 7, 2025 · After close−2.1%
Q4 2024Mar 10, 2025+18.7%
Q3 2024Nov 6, 2024 · After close+12.1%
Q2 2024Aug 8, 2024 · After close−1.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close−3.4%
Q4 2023Mar 18, 2024 · After close−6.0%
Q3 2023Nov 8, 2023 · After close−3.6%
Q2 2023Aug 9, 2023 · After close+5.5%
Q1 2023May 10, 2023 · After close+7.7%
Q4 2022Mar 8, 2023 · After close−12.6%
Q3 2022Nov 10, 2022 · After close+30.9%
Q2 2022Aug 10, 2022 · After close−0.6%
Q1 2022May 11, 2022 · After close+7.1%
Q4 2021Mar 23, 2022 · After close+12.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck34 slidesSeptember 2026
Technical Presentation (June 2026)Technical27 slidesJun 3, 2026
Jefferies Global Healthcare Conference 2026Conference41 slidesJune 2026
Technical Presentation (May 2026)Technical30 slidesMay 15, 2026
ASGCT 2026Conference13 slidesMay 15, 2026
Technical Presentation (August 2025)Technical30 slidesAug 26, 2025
Investor Presentation (April 2025)Investor deck50 slidesApril 2025
Technical Presentation (2025)Technical15 slides2025
Technical Presentation (December 2024)Technical28 slidesDec 17, 2024
Technical Presentation (2022)Technical15 slides2022

Open Decks

Financings

RaiseDate
Public offering of units and pre-funded units
Announced: US$60M · US$1.2 a unit · Warrants at US$1.5 for 60 months · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), LifeSci Capital
Use of proceeds: Development of clinical and early-stage candidates, particularly TN-201 and TN-401, plus working capital and general corporate purposes
Dec 11, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$15.00 a share on Jul 29, 2021.

Price
US$15.00 a share
Shares offered
12,000,000 shares of common stock
Offering size
US$180 million
Underwriters' option
Up to 1,800,000 more shares
Underwriters
Morgan Stanley, Cowen, Piper Sandler, Chardan · In the order on the cover
Shares delivered
On or about Aug 3, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 7, 2021
Filed publiclyJul 9, 2021
Amended onceJul 26, 2021
Shares registered with an exchangeJul 23, 2021
Declared effective by the SECJul 29, 2021
Final prospectus, with the priceJul 30, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue0000000
Cost of revenue8.44M8.47M8.69M8.71M4.03M2.48M1.99M
Gross profit-8.44M-8.47M-8.69M-8.71M-4.03M-2.48M-1.99M
Research and development68.6M86.7M98.0M94.5M54.4M31.1M23.1M
Selling, general and administrative24.7M29.2M33.2M31.1M18.4M7.81M4.56M
Operating income-93.3M-115.9M-131.2M-125.6M-72.8M-38.9M-27.7M
Depreciation and amortization8.44M8.47M8.69M6.47M2.96M2.48M1.99M
EBITDA-84.9M-107.5M-122.5M-119.2M-69.8M-36.4M-25.7M
Interest expense1.96K72.7M00
Income before tax-90.6M-111.1M-124.1M-123.7M-72.7M-38.4M-26.2M
Income tax000000-453.0K
Net income-90.6M-111.1M-124.1M-123.7M-72.7M-38.4M-25.8M
Earnings per share, basic-0.59-1.31-1.68-2.76-4.10-39.50-0.95
Earnings per share, diluted-0.59-1.31-1.68-2.76-4.10-39.50

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents100.5M4.32M45.7M95.3M38.1M128.5M23.9M
Short-term investments057.1M59.0M91.3M213.2M02.75M
Receivables2.25M
Inventory-19.9M
Current assets105.6M67.4M111.6M193.8M255.4M130.0M27.7M
Property, plant and equipment27.7M35.9M43.3M51.0M43.0M17.2M9.57M
Total assets146.9M119.9M170.5M278.9M314.2M148.2M38.0M
Accounts payable3.58M5.16M5.63M9.58M10.7M1.02M600.0K
Current liabilities15.4M16.0M22.7M24.2M21.8M5.04M4.12M
Total debt10.8M13.6M12.4M15.1M15.7M
Total liabilities23.7M27.1M31.1M35.6M35.7M8.72M81.7M
Shareholders' equity123.3M92.9M139.4M243.4M278.5M-81.3M-43.7M
Shares outstanding216.8M86.5M68.3M66.9M41.3M1.21M27.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-68.3M-90.5M-102.1M-104.4M-60.8M-35.4M-24.1M
Capital spending-618.0K-1.02M-1.24M-20.6M-25.1M-9.76M-2.93M
Free cash flow-68.9M-91.5M-103.3M-125.1M-85.9M-45.2M-27.0M
Cash from investing56.1M1.13M48.7M83.7M-238.6M-7.01M-5.58M
Cash from financing108.4M47.7M4.05M77.8M209.0M147.3M30.5M
Share buybacks77.8M-13.0K-1.00K-3.00K
Change in cash96.2M-41.6M-49.3M57.0M-90.4M104.8M832.0K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
DEFA14A · Additional proxy materialOct 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementOct 23, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 13, 2026Meeting noticeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeAug 24, 2026Big-stake noticeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
S-8 · Registration statement for employee plansAug 5, 2026Offer documentSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
3 · Initial statement of ownershipJul 14, 2026Insider tradeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
8-K · Current reportJul 2, 2026Current reportSEC
8-K · Current reportJun 29, 2026Management or board changeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
8-K · Current reportMay 29, 2026Management or board changeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
8-K · Current reportMay 6, 2026ResultsSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
10-K · Annual reportMar 11, 2026Annual reportSEC
8-K · Current reportMar 11, 2026ResultsSEC
8-K · Current reportMar 5, 2026Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 26, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
144 · Notice of proposed saleFeb 20, 2026Other filingsSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
144 · Notice of proposed saleFeb 17, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 11, 2026Other filingsSEC
144 · Notice of proposed saleFeb 10, 2026Other filingsSEC
144 · Notice of proposed saleFeb 10, 2026Other filingsSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
S-8 · Registration statement for employee plansFeb 3, 2026Offer documentSEC
8-K · Current reportJan 30, 2026Management or board changeSEC
8-K · Current reportJan 2, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 17, 2025Big-stake noticeSEC
8-K · Current reportDec 12, 2025Material contractSEC
424B5 · ProspectusDec 12, 2025Offer documentSEC
424B5 · ProspectusDec 11, 2025Offer documentSEC
8-K · Current reportDec 11, 2025Current reportSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
8-K · Current reportNov 7, 2025Current reportSEC
UPLOAD · Letter from the SECSep 10, 2025Other filingsSEC
CORRESP · Letter to the SECSep 4, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 26, 2025Other filingsSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
144 · Notice of proposed saleAug 18, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
4 · Change in ownershipMay 30, 2025Insider tradeSEC
8-K · Current reportMay 30, 2025Meeting outcomeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
4 · Change in ownershipMay 16, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeMay 7, 2025Big-stake noticeSEC
8-K · Current reportApr 18, 2025Current reportSEC
ARS · Annual report to shareholdersApr 17, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 1, 2025Other filingsSEC
8-K · Current reportMar 28, 2025Current reportSEC
CORRESP · Letter to the SECMar 27, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 26, 2025Other filingsSEC
S-3 · Registration statementMar 21, 2025Offer documentSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 10, 2025Insider tradeSEC
144 · Notice of proposed saleMar 10, 2025Other filingsSEC
144 · Notice of proposed saleMar 10, 2025Other filingsSEC
10-K · Annual reportMar 10, 2025Annual reportSEC
8-K · Current reportMar 10, 2025ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 7, 2025Big-stake noticeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
4 · Change in ownershipMar 7, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2025Big-stake noticeSEC
8-K · Current reportMar 4, 2025Material contractSEC
424B5 · ProspectusMar 4, 2025Offer documentSEC
424B5 · ProspectusMar 3, 2025Offer documentSEC
424B3 · ProspectusMar 3, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
3 · Initial statement of ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 7, 2025Offer documentSEC
8-K · Current reportFeb 7, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
8-K · Current reportJan 28, 2025Management or board changeSEC
8-K · Current reportDec 17, 2024Current reportSEC
8-K · Current reportDec 17, 2024Management or board changeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
S-8 · Registration statement for employee plansSep 17, 2024Offer documentSEC
8-K · Current reportSep 16, 2024Management or board changeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 19, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
144 · Notice of proposed saleAug 16, 2024Other filingsSEC
144 · Notice of proposed saleAug 16, 2024Other filingsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJul 25, 2024Management or board changeSEC
8-K · Current reportJun 27, 2024Management or board changeSEC
8-K · Current reportMay 31, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
ARS · Annual report to shareholdersApr 17, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2024Meeting noticeSEC
10-K · Annual reportMar 18, 2024Annual reportSEC
8-K · Current reportMar 18, 2024ResultsSEC
4 · Change in ownershipMar 6, 2024Insider tradeSEC
144 · Notice of proposed saleMar 5, 2024Other filingsSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 27, 2024Insider tradeSEC
4 · Change in ownershipFeb 21, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 20, 2024Other filingsSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
4 · Change in ownershipFeb 16, 2024Insider tradeSEC
144 · Notice of proposed saleFeb 16, 2024Other filingsSEC
144 · Notice of proposed saleFeb 16, 2024Other filingsSEC
144 · Notice of proposed saleFeb 16, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
424B5 · ProspectusFeb 8, 2024Offer documentSEC
8-K · Current reportFeb 8, 2024Material contractSEC
S-8 · Registration statement for employee plansJan 31, 2024Offer documentSEC
SC 13G · Big-stake noticeJan 31, 2024Big-stake noticeSEC

This page holds 200 of 356 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Tenaya Therapeutics, Inc.’s releases · as of Oct 29, 2026

Common shares
227,928,240
Fully diluted
227,928,240

Fully diluted

LineSharesAs of
Common shares227,928,240Oct 29, 2026

Share count over time

CountShares
Oct 29, 2026227,928,240

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Millennium10.2M4.5%US$6.18M+3.82MNov 16, 2026
Vanguard9.42M4.1%US$5.69M+1.24MNov 16, 2026
Citadel4.51M2.0%US$2.72M−61,691Nov 16, 2026
BlackRock4.2M1.8%US$2.54M+191KNov 13, 2026
Renaissance Technologies2.96M1.3%US$1.79M−1.32MNov 12, 2026
Marshall Wace, LLP2.57M1.1%US$1.54M−935KNov 13, 2026
Geode Capital2.2M0.97%US$1.33M+366KNov 6, 2026
Empery Asset Management, LP2.13M0.93%US$1.28M−1.73MNov 16, 2026
ADAR1 Capital Management, LLC1.56M0.68%US$939KNo changeNov 16, 2026
Raiffeisen Bank International AG1.2M0.53%US$712KNo changeOct 28, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Gsa Capital Partners LLP1.09M0.48%US$660K−1.58MNov 16, 2026
Euclidean Capital LLC1.02M0.45%US$613KNo changeNov 16, 2026
Two Sigma1M0.44%US$605K+622KNov 16, 2026
Mirador Capital Partners LP957K0.42%US$578K+52,107Oct 9, 2026
State Street760K0.33%US$459K+51,600Nov 12, 2026
Northern Trust508K0.22%US$307K+162KNov 16, 2026
Invesco488K0.21%US$294K+133KNov 12, 2026
StepStone Group LP462K0.20%US$277KNo changeNov 17, 2026
Morgan Stanley368K0.16%US$222K+136KNov 13, 2026
Casdin Capital, LLC362K0.16%US$218KNo changeNov 16, 2026
Acadian Asset Management LLC300K0.13%US$178K+97,060Nov 9, 2026
DAFNA Capital Management LLC300K0.13%US$181KNo changeNov 16, 2026
Schwab251K0.11%US$152KNewNov 16, 2026
Susquehanna243K0.11%US$146K−82,617Nov 16, 2026
Goldman Sachs218K0.10%US$131K−76,930Nov 16, 2026
Almanack Investment Partners, LLC.163K0.07%US$98,508−5,000Nov 3, 2026
UBS129K0.06%US$77,709−328KNov 10, 2026
Graham Capital Management, L.P.110K0.05%US$66,319NewNov 16, 2026
Squarepoint Ops LLC101K0.04%US$61,003−558KNov 9, 2026
BMO83,8500.04%US$50,612NewNov 9, 2026
Wealth Enhancement Advisory Services, LLC78,5410.03%US$42,742+2,358Oct 13, 2026
Pathstone Holdings, LLC75,0000.03%US$45,270No changeNov 13, 2026
R Squared Ltd74,3500.03%US$44,878+42,847Nov 5, 2026
Spark Investment Management LLC68,7000.03%US$41,467+33,200Nov 13, 2026
Dimensional64,9040.03%US$39,176No changeNov 4, 2026
Cetera Investment Advisers57,1250.03%US$34,481No changeNov 13, 2026
Callan Family Office, LLC50,0610.02%US$30,217No changeNov 13, 2026
Centaurus Financial, Inc.50,0000.02%US$30,000NewNov 12, 2026
China Universal Asset Management Co., Ltd.40,9130.02%US$24,266+6,378Oct 27, 2026
BridgePort Financial Solutions, LLC40,0000.02%US$24,144NewNov 2, 2026
Citizens Financial Group Inc36,0000.02%US$21,730+18,000Oct 23, 2026
Osaic Holdings, Inc.34,5630.02%US$20,398No changeNov 12, 2026
T. Rowe Price31,8390.01%US$20,000+386Nov 16, 2026
Integrated Wealth Concepts LLC27,4400.01%US$16,563−20,440Nov 16, 2026
Ewa, LLC25,7760.01%US$15,558−2,880Nov 17, 2026
Victory Capital25,2870.01%US$15,263+892Nov 10, 2026
Quantinno Capital Management LP24,3020.01%US$14,669+2,830Nov 13, 2026
BNY24,0060.01%US$14,490No changeNov 5, 2026
HighPoint Advisor Group LLC21,300<0.01%US$12,857No changeNov 9, 2026
Barclays20,375<0.01%US$12,298+7,230Nov 6, 2026

This page holds 50 of 94 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund5.14M2.3%US$3.8M−1.34MJun 30, 2026
Vanguard Extended Market Index Fund1.77M0.78%US$1.31M−6,303Jun 30, 2026
iShares Biotechnology ETF1.49M0.65%US$1.1M+291KJun 30, 2026
Fidelity Extended Market Index Fund824K0.36%US$716K+271KMay 31, 2026
Fidelity Total Market Index Fund303K0.13%US$263K+128KMay 31, 2026
Fidelity Series Total Market Index Fund231K0.10%US$201K+84,355May 31, 2026
Invesco RAFI US 1500 Small-Mid ETF222K0.10%US$164K+96,700Jul 31, 2026
Ultra-Small Company Market Fund175K0.08%US$129KNo changeJun 30, 2026
Goldman Sachs Absolute Return Tracker Fund162K0.07%US$120K+141KJun 30, 2026
Fidelity Nasdaq Composite Index Fund120K0.05%US$105KNo changeMay 31, 2026
All 19 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Institutional Total Stock Market Index Fund113K0.05%US$83,690No changeJun 30, 2026
Vanguard Balanced Index Fund83,2600.04%US$61,537−35,122Jun 30, 2026
T. Rowe Price Total Equity Market Index Fund31,4530.01%US$23,247No changeJun 30, 2026
Victory Extended Market Index Fund24,3950.01%US$18,060+5,904Jul 31, 2026
Invesco Nasdaq Biotechnology ETF11,421<0.01%US$9,925+2,137May 31, 2026
ProShares Ultra Nasdaq Biotechnology8,012<0.01%US$6,962+324May 31, 2026
AST Small-Cap Equity Portfolio4,770<0.01%US$3,526No changeJun 30, 2026
Total Stock Market Index Trust3,852<0.01%US$2,847+742Jun 30, 2026
Avantis Total Equity Markets ETF3,673<0.01%US$3,192No changeMay 31, 2026

Insider trades

InsiderTradeSharesPriceValueDate
Tingley Whittemore
Officer: Chief Medical Officer
Sale3,223USD 0.32US$1,034Nov 17, 2026
Ali Faraz
Director, Officer: Chief Executive Officer
Sale3,499USD 0.32US$1,122Nov 17, 2026
Tingley Whittemore
Officer: Chief Medical Officer
Sale1,637USD 0.71US$1,162Aug 17, 2026
Tingley Whittemore
Officer: Chief Medical Officer
Sale1,871USD 0.71US$1,328Aug 17, 2026
Tingley Whittemore
Officer: Chief Medical Officer
Sale2,279USD 0.71US$1,618Aug 17, 2026
Ali Faraz
Director, Officer: Chief Executive Officer
Sale5,837USD 0.71US$4,144Aug 17, 2026
Ali Faraz
Director, Officer: Chief Executive Officer
Sale3,969USD 0.71US$2,818Aug 17, 2026
Ali Faraz
Director, Officer: Chief Executive Officer
Sale5,020USD 0.71US$3,564Aug 17, 2026
Ali Faraz
Director, Officer: Chief Executive Officer
Sale7,406USD 0.71US$5,258Aug 17, 2026
Higa Tomohiro
Officer: SVP, Finance
Sale1,485USD 0.79US$1,173May 18, 2026
All 12 trades
InsiderTradeSharesPriceValueDate
Tingley Whittemore
Officer: Chief Medical Officer
Sale3,121USD 0.79US$2,466May 18, 2026
Ali Faraz
Director, Officer: Chief Executive Officer
Sale3,390USD 0.79US$2,678May 18, 2026

Big stakes

HolderStakeSharesDate
The Column Group Opportunity III, LP21.60%49.3MSep 30, 2026
Integrated Core Strategies (US) LLC5.20%11.6MAug 17, 2026
Casdin Capital, LLC4.30%6.73MMar 4, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Eli Casdin
Other companies: Standard BioTools Inc. (Director · Since at least Apr 4, 2022); GeneDx Holdings Corp. (Board Member · Since at least Sep 1, 2020); 2Seventy Bio Inc (Director · Mar 20, 2024 – May 13, 2025 · Past); EQRx Inc (Director · Dec 17, 2021 – Sep 30, 2022 · Past); Absci Corporation (Director · Jul 21, 2021 – Jun 8, 2022 · Past); Century Therapeutics, Inc. (Director · Jun 17, 2021 – Jun 9, 2022 · Past); CM Life Sciences III Inc. (Officer (CEO), Director · Apr 6, 2021 – Aug 1, 2021 · Past); EXACT Sciences Corporation (Director · Oct 26, 2017 – Jul 23, 2020 · Past)
Director · Jul 29, 2021 – Nov 17, 2022 · Past
Leone Patterson
Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Apr 3, 2025); Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Nkarta, Inc. (Member of Board of Directors · Since at least Jul 9, 2020); Climb Bio, Inc. (Director · Aug 9, 2021 – May 19, 2022 · Past); Adverum Biotechnologies Inc (President and CFO · Jun 15, 2016 – Feb 16, 2021 · Past); Paratek Pharmaceuticals Inc (Vice President, CFO · Jun 25, 2012 – Oct 30, 2014 · Past)
Chief Fin. and Bus. Officer · Jul 29, 2021 – Feb 23, 2024 · Past
Karah Parschauer
Other companies: Evolus, Inc. Common Stock (Director · Since at least Jul 15, 2019); Ultragenyx Pharmaceutical Inc. (EVP and Chief Legal Officer · Since at least Jun 20, 2016); Anebulo Pharmaceuticals, Inc. (Director · May 6, 2021 – Apr 21, 2022 · Past); Arcturus Therapeutics Holdings Inc. (Director · Jun 19, 2019 – Jun 18, 2021 · Past)
Board Member · Since at least Dec 22, 2021
Catherine Stehman-Breen
Other companies: Dyne Therapeutics, Inc. (Board Member · Since at least Jul 31, 2020); Generation Bio Co (Director · Since at least Jun 11, 2020); Sarepta Therapeutics, Inc. (SVP, Chief Medical Officer · Apr 3, 2017 – Apr 3, 2017 · Past)
Board Member · Since at least Jul 29, 2021
David V Goeddel
Other companies: Nurix Therapeutics, Inc. (Director · Jul 28, 2020 – Jul 28, 2020 · Past); RAPT Therapeutics Inc (Director · Oct 30, 2019 – Nov 4, 2019 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 5, 2024 · Past)
Director · Since at least Jul 29, 2021
June Lee
Other companies: Eledon Pharmaceuticals, Inc. (Director · Since at least Dec 8, 2020); CinCor Pharma Inc (Director · Jan 6, 2022 – Feb 24, 2023 · Past); MyoKardia Inc (EVP, Chief Development Officer · Jan 31, 2017 – Oct 29, 2019 · Past)
Board Member · Since at least Nov 19, 2021
R. Sanders Williams
Other companies: Amgen Inc. (Director · Oct 17, 2014 – May 19, 2023 · Past); Labcorp Holdings Inc. (Director · May 16, 2007 – Feb 6, 2024 · Past); Bristol-Myers Squibb Company (Director · Sep 11, 2006 – Feb 1, 2013 · Past)
Chair of the Board · Since at least Jul 29, 2021
Amy Burroughs
Other companies: Terns Pharmaceuticals, Inc. (Chief Executive Officer, Director · Since at least Feb 7, 2024); DiaMedica Therapeutics Inc. (Director · Jul 15, 2021 – Jan 3, 2023 · Past)
Board Member · Since at least Dec 5, 2022
Eric Hyllengren
Other companies: Zura Bio Limited (Chief Financial Officer · Since at least Jul 1, 2025); Atara Biotherapeutics, Inc. (EVP, CFO and COO · Apr 1, 2023 – Mar 3, 2025 · Past)
Chief Financial Officer · Since at least Jun 29, 2026
Faraz Ali
Other companies: Regenxbio Inc. (Chief Business Officer · Feb 29, 2016 – Jan 4, 2017 · Past)
Chief Executive Officer · Since at least Jul 29, 2021
All 25 people
PersonSeat
Jeffrey T. Walsh
Other companies: Bluebird bio Inc (Chief Strategy Officer · Mar 11, 2019 – Aug 20, 2019 · Past)
Board Member · Since at least Jul 29, 2021
Jin-Long Chen
Other companies: NGM Biopharmaceuticals Inc (Chief Scientific Officer, Director · Apr 3, 2019 – Mar 2, 2023 · Past)
Director · Jul 29, 2021 – Jun 9, 2023 · Past
Timothy Hoey
Other companies: OncoMed Pharmaceuticals Inc (SVP, Cancer Biology & Co-CSO · Jul 17, 2013 – Apr 23, 2017 · Past)
Chief Scientific Officer · Jul 29, 2021 – Mar 5, 2024 · Past
Chihiro SaitoSVP, Accounting and Fin. Ops. · Aug 14, 2024 – Nov 18, 2024 · Past
Deepak SrivastavaBoard Member · Since at least Jul 29, 2021
Hiro HigaSenior Vice President · Until Jun 29, 2026 · Past
Jay VoraSenior Vice President, Portfolio and Program Management · Since at least Nov 4, 2026
JeenJoo KangDirector · Jul 29, 2021 – Aug 3, 2021 · Past
Jennifer DrimmerGeneral Counsel · Since at least Nov 4, 2026
Joanna AuchSenior Vice President, People and Culture · Since at least Nov 4, 2026
Kathy IveySenior Vice President, Research · Since at least Mar 9, 2026
Kee-Hong KimChief Technology Officer · Since at least Nov 4, 2026
Tomohiro HigaSVP, Finance · Since at least Feb 6, 2025
Whittemore TingleyChief Medical Officer · Since at least Jul 29, 2021
Whit TingleyChief Medical Officer · Since at least Jun 3, 2026

Open People

Log in to ask 6ix AI your own questions about Tenaya Therapeutics, Inc.